Acetaminophen (APAP) induced increases in intrahepatic expression of interleukin (IL)-1a, IL-1b, and IL-1 receptor antagonist (IL-1ra), when administered intraperitoneally. These observations prompted us to define the pathophysiological roles of IL-1ra in APAP-induced liver injury. Compared with wild-type (WT) mouse-derived hepatocytes, IL-1ra-deficient (IL-1ra KO)-derived hepatocytes exhibited more resistance against APAP but not APAP-derived major toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). Moreover, the amounts of a major APAP adduct (selenium-binding protein), an indicator of NAPQI generation from APAP, was significantly lower in IL-1ra KO mice than WT mice with depressed intrahepatic expression of CYP1A2, CYP2E1, and CYP3A11, the enzymes crucially involved in NAPQI generation from APAP. These observations would indicate that IL-1ra deficiency impaired APAP metabolism. IL-1a and IL-1b were expressed to similar extents in livers of untreated IL-1ra KO and WT mice. By contrast, the intranuclear amount of p65 of NF-kB, which can suppress the gene expression of CYP1A2, CYP2E1, and CYP3A11, was higher in untreated IL-1ra KO than WT mice. Moreover, when mice were intraperitoneally administered APAP (200 mg/kg), IL-1ra KO mice exhibited attenuated APAP-induced liver injury as evidenced by reductions in serum alanine transferase levels and histopathological changes such as centrilobular necrosis, hemorrhages, and leukocyte infiltration. Finally, when given 12 h before APAP challenge, IL-1a repressed the intrahepatic expression of CYP1A2, CYP2E1, and CYP3A11, eventually reducing APAP-induced liver injury, along with reduction in APAP adducts. Collectively, NF-kB was activated without any stimuli by the genetic disruption of IL-1ra, and suppressed cytochrome P450 enzyme expression, thereby reducing APAP-induced liver injury.
inflammatory cytokines, chemokines, and leukocytes have some detrimental roles in the pathogenesis of APAP-induced liver injury. [5] [6] [7] Interleukin-1 (IL-1), a pleiotropic proinflammatory cytokine, is produced by various kinds of cells such as neutrophils, macrophages, and fibroblasts. IL-1a and IL-1b, encoded by two distinct genes, show similar biological activities after binding to their specific and common receptor, type I IL-1 receptor (IL-1RI). 8 IL-1 receptor antagonist (IL-1ra), exhibiting an identical b-pleated sheet structure as IL-1s, 9 ,10 can bind to IL-1R at the same sites with a similar affinity as IL-1s, 11 but fails to associate with IL-1R accessory protein, which is indispensable for the biological activities of IL-1s. 12 Thus, IL-1ra antagonizes IL-1 by binding to IL-1RI in a competitive manner. In various inflammatory diseases, such as rheumatoid arthritis and infectious diseases, IL-1ra is abundantly produced along with IL-1, probably to dampen the bioactivities of aberrantly produced IL-1s. 11, 13 Mirroring its proinflammatory activity on IL-1, mice lacking IL-1ra (IL1ra KO mice) spontaneously developed polyarthritis with increasing age.
14 Consistently, we also observed that the lack of IL-1ra enhanced inflammatory responses during skin wound healing. 15 In APAP-induced liver injury, intrahepatic IL-1 production was correlated with the magnitude of organ damage. [4] [5] [6] Moreover, Blazka et al 16, 17 demonstrated that the administration of anti-IL-1 antibody attenuated APAP-induced liver injury. Thus, we hypothesized that the genetic disruption of IL-1ra enhanced APAP-induced liver injury with aberrant inflammatory responses. Unexpectedly, APAP-induced liver injury was attenuated in IL-1ra KO mice, together with reduced generation of APAP adducts, the molecules involved crucially in APAP-induced liver injury, compared with wildtype (WT) mice. We further provided evidence to indicate that constitutive NF-kB activation in IL-1ra KO mice suppressed the intrahepatic expression of cytochrome P450 enzymes, which can generate NAPQI. Thus, the balance between IL-1s and IL-1ra expression in liver could affect the susceptibility of APAP-induced liver injury by modulating intrahepatic cytochrome P450 enzyme expression.
MATERIALS AND METHODS Reagents and Antibodies
Acetaminophen and NAPQI were purchased from Sigma Chemical Company (St Louis, MO). The following monoclonal antibodies (mAbs) or polyclonal Abs (pAbs) were used in the present study: rat anti-mouse F4/80 mAb (Dainippon Pharmaceutical Company, Osaka, Japan), rabbit anti-myeloperoxidase (MPO) pAbs (Neomarkers, Fremont, CA), rabbit anti-APAP pAbs (Biogenesis Inc., Kingston, NH), rabbit anti-CYP1A2 pAbs, rabbit anti-CYP3A pAbs, rabbit anti-b-actin pAbs, rabbit anti-mouse NF-kB p65 pAbs (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), rabbit anti-CYP2E1 pAbs (Daiichi, Pure Chemicals, Tokyo, Japan), and rabbit anti-single-strand DNA (ssDNA) pAbs (Dako, Kyoto, Japan). Recombinant murine IL-1ra and IL-1a proteins were prepared as described previously. 18, 19 Mice Pathogen-free 8-to 10-week-old male BALB/c mice were obtained from Sankyo Laboratories (Tokyo, Japan) and were designated as WT mice in the present experiments. Age-and sex-matched IL-1ra KO mice, backcrossed to BALB/c mice for more than eight generations, were used in the following experiments. 15, 20 All mice were housed individually in cages under the specific pathogen-free conditions during the experiments. All animal experiments were approved by the Committee on Animal Care and Use in Wakayama Medical University.
Isolation and Culture of Mouse Hepatocytes
Mouse hepatocytes were isolated and cultured as describe previously. 21 Briefly, calcium-and magnesium-free Hanks' solution supplemented with EGTA (0.5 mM) and Tris (25 mM, pH 7.4) was perfused through the liver via the portal vein for 15 min at 371C The liver was then perfused with media-containing 0.05% collagenase (Gibco, Long Island, NY) at a flow rate of 5 ml/min for 20 min. Thereafter, the liver was removed, minced, and filtered. Hepatocytes were separated from nonparenchymal cells and debris by the centrifugation at 50 g for 1 min. Cell viability, as judged by Trypan blue exclusion, was usually 480%. Isolated hepatocytes were cultured onto a 96-well plate (2 Â 10 4 cells per well) in Williams's medium E (Gibco) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin/streptomycin and 10 À7 M insulin at 371C with 5% CO 2 . After 4 h incubation, cells were washed with PBS and then replaced with plain culture medium (control) or medium-containing APAP (5 mM) or NAPQI (400 mM). At 4 h later, cells were washed with PBS and then replaced with plain medium. The viability of hepatocytes was assessed by using a Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. The data were expressed as percentage (%) of post-treatment to pretreatment viabilities. In some experiments, isolated hepatocytes from WT mice were cultured with rIL-1a (10 ng/ml) or rIL-1ra (40 ng/ml) for 6 h, and subjected to the following analyses.
APAP-Induced Liver Injury in Mice
In all experiments, mice were allowed free access to water but not food for 10 h before APAP challenge. APAP solution was made by dissolving the compound in phosphate-buffered saline (PBS, pH 7.2) and warmed to 371C immediately before each experiment. Mice were intraperitoneally administered with APAP at the doses of 100-300 mg/kg in preliminary experiments. We observed that 200 mg/kg was the highest dose that did not cause any mortality in WT mice and therefore, we used this dose unless indicated otherwise. In some experiments, mice were intraperitoneally administrated with rIL-1a (1 mg/mouse), or rIL-1ra (40 mg/mouse) at 12 h before APAP challenge (200 mg/kg).
Determination of Serum Alanine Aminotransferase Levels
Whole-blood samples were collected at the indicated time intervals after APAP challenge to determine serum alanine transferase (ALT) levels with a Fuji DRI-CHEM 3500 V as instructed by the manufacturer (Fuji Medical System, Tokyo, Japan).
Histopathological Analysis
Liver tissues were obtained at the indicated time intervals after APAP challenge and were fixed in 4% formaldehyde buffered with PBS (pH 7.2) and then embedded with paraffin. Thereafter, sections (6 mm thick) were stained with hematoxylin and eosin. Pathological changes in the livers were evaluated by an examiner without a prior knowledge of the experimental procedures and scored as follows; 0, no necrosis; 1 þ , minimal centrilobular necrosis; 2 þ , severe necrosis but confined to centrilobular regions; 3 þ , necrosis extending from central zone to portal triads; 4 þ , massive necrosis spreading most regions.
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Enumeration of Infiltrating Inflammatory Cells and Apoptotic Hepatocytes An immunohistochemical analysis was performed using anti-MPO pAbs for neutrophils, anti-F4/80 mAb for macrophages, and anti-ssDNA pAbs for apoptotic hepatocytes, as described previously. [5] [6] [7] The numbers of infiltrating neutrophils, macrophages, and apoptotic hepatocytes in the liver were enumerated on 10 randomly chosen visual fields at Â 400 magnification and the average of the 10 fields was calculated. 7 All measurements were performed by an examiner without a prior knowledge of the experimental procedures.
Extraction of Total RNAs and Semiquantitative RT-PCR
Total RNAs was extracted from the removed liver tissues using ISOGEN (Nippon Gene, Toyama, Japan), followed by a semiquantitative RT-PCR analysis, as described previously. [5] [6] [7] Briefly, 5 mg of total RNAs was reverse transcribed into cDNA using the Superscript II Reverse Transcriptase (Invitrogen Life Technologies, Tokyo, Japan) with Oligo (dT) Primers (Invitrogen Life Technologies). The resultant cDNA was amplified with Taq polymerase (Nippon Gene, Tokyo, Japan), using specific sets of primers with optimal cycles consisting of 941C for 1 min, optimal annealing temperature for 1 min, and 721C for 1 min, followed by the incubation at 721C for 3 min (Table 1 ). The PCR products were then fractionated on a 2% agarose gel containing 0.3% ethidium bromide, and the band intensities were measured using NIH Image Analysis software version 1.63 (National Institutes of Health, Bethesda, MD). The ratio of each band to b-actin was determined. To standardize the condition of gel staining, a constant amount of control DNA marker was electrophoresed every time. The PCR procedure was performed at least three times for each sample.
Western Blotting
In some experiments, liver samples or hepatocytes (1 Â 10 6 ) were homogenized with a lysis buffer (10 mM PBS, 1% NP-40, 4 mM EDTA) containing Complete Protease Inhibitor Cocktail (Roche Diagnostics, Tokyo, Japan) and centrifuged to obtain lysates. The lysates were electrophoresed in a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. After the immersion with the blocking buffer (10 mM Tris-HCl, pH 7.4, containing 0.5 M NaCl, 5% skim milk, and 0.5% Tween-20), the membrane was incubated with anti-APAP pAbs, anti-CYP1A2 pAbs, anti-CYP2E1 pAbs, anti-CYP3A pAbs, or anti-b-actin pAbs at 41C overnight. After the incubation with horseradish peroxidaseconjugated secondary Abs for 1 h at room temperature, the immune complexes were detected by using ECL-western blotting detection system (Amersham Bioscience Japan, Tokyo, Japan) according to the manufacturer's instructions. The band intensities were measured using NIH Image Analysis software version 1.63 (National Institutes of Health, Bethesda, MD). The ratio of each band to b-actin was determined.
Measurement of Intrahepatic Glutathione
Liver tissues were obtained at indicated time interval after APAP challenge and were homogenized in 5% metaphosphoric acid. The homogenates were centrifuged at 3000 g for 10 min. GSH levels in the supernatant were measured with a commercial GSH measurement kit (BIOXYTECH GSH400, OxisRsearch, Portland, OR) according to the manufacturer's instruction. The data were expressed as GSH (nmol)/liver weight (g).
Enzyme-Linked Immunosorbent Assay
Livers were obtained and homogenized with 0.3 ml PBS containing Complete Protease Inhibitor Cocktail (Roche Diagnostics), followed by three cycles of freezing and thawing. The homogenates were centrifuged at 10 000 g for 15 min. Supernatants were used to determine IL-1ra, IL-1a, IL-1b, IL-6, and IL-10 levels with enzyme-linked immunosorbent assay kits (IL-1ra, IL-1a, and IL-1b; R&D Systems, Minneapolis, IL-6; COSMO BIO, Tokyo, Japan, IL-10; Bender Medsystems Inc., Burlingame, CA) according to the manufacturer's instructions. The detection limits were as follows: IL-1ra, 47 pg/ml, IL-1a, 42.5 pg/ml, IL-1b, 43 pg/ ml, IL-6, 43 pg/ml, and IL-10, 415 pg/ml. Total protein in the supernatant was measured with a commercial kit (BCA protein assay kit, Pierce, Rockford, IL), using BSA as a standard. The data were expressed as the target molecule (pg/ ml)/total protein (mg/ml) for each sample.
Extraction of Nuclear Proteins and Measurement of NF-jB p65 Protein
Cell lysates from livers or hepatocytes (1 Â 10 6 ) were further separated into cytosol and nuclear fractions using the NE-PER method (Pierce) as described previously. 22 Each fraction was subjected to western blotting using anti-NF-kB p65 pAbs. In parallel, nuclear fractions were analyzed by using an EZ-Detect Transcription Factor kit (Pierce) to determine NFkB p65 protein bound to the corresponding cis element, according to the manufacturer's instructions. The NF-kB activities were expressed as relative light units divided by total protein contents for each sample.
Determination of Blood APAP Concentrations by Gas Chromatography-Mass Spectrometry At the indicated time intervals after APAP administration (200 mg/kg), the blood samples were collected from both strain mice. The blood samples were mixed with internal standard solution (o-acetamidephenol; 10 mg/10 ml) and 0.1 M borate sodium buffer (pH 10.5), followed by the adjustment of pH to 10 with 0.5 N sodium hydroxide solution. Then, the mixture was applied to an Extrelut NT s column (Merck), followed by the elution with ethyl acetate. The eluate was condensed and was converted to trimethylsilyl (TMS) derivatives with N,O-bis[trimethylsilyl]trifluoroacetamide þ 1% trimethylchlorosilane. The solution (1 ml) was applied onto a gas chromatography-mass spectrometry apparatus (A model Trace GC and MS system, Thermo Fisher Scientific, CA). Quantity of APAP was determined as the average area ratio of APAP-TMS (5.77 min, m/z 166 and 181) to o-acetamidephenol-TMS (5.10 min, m/z 166) as an internal standard.
Statistical Analysis
The means and s.e.m.s were calculated for all parameters determined in this study. Statistical significance was evaluated using analysis of variance or Mann-Whitney's U-test. Po0.05 was accepted as statistically significant. 
RESULTS

Reduced Susceptibility of IL-1ra-Deficient Hepatocytes to APAP Toxicity
At first, we examined the susceptibility of cultured hepatocytes derived from WT and IL-1ra KO mice to APAP and its toxic metabolite, NAPQI. WT mouse-derived hepatocytes were more sensitive to APAP than IL-1ra KO mouse-derived ones, in terms of cell survival rates, although both hepatocytes showed similar sensitivities to NAPQI (Figure 1a) . NAPQI, once generated from APAP, covalently binds to cysteine residues on proteins and induces the formation of 3-(cysteine-S-yl) APAP adducts, which is presumed to be responsible for APAP-induced hepatotoxicity. Thus, it is probable that there exist differences in the NAPQI and subsequent APAP adduct generation between WT and IL-1ra KO mice. To address this assumption, we determined the amount of the major APAP adduct (56 kDa selenium-binding protein) reflecting NAPQI amounts in the homogenates of hepatocytes and livers. After APAP addition to the culture medium, the amounts of APAP adducts were higher in WTderived hepatocytes, than IL-1ra KO-derived ones ( Figure  1b ). In livers of untreated WT and IL-1ra KO mice, APAP adducts were barely detected, but the intraperitoneal injection of APAP (100-300 mg/kg) increased the amount of APAP adducts in a dose-dependent manner to a larger extent in WT mice than in IL-1ra KO ones (Figure 1c) . 23, 24 We next examined blood APAP concentration and intrahepatic GSH levels in both strain mice at 1 and 2 h after APAP challenge (200 mg/kg), because the half-life of APAP was 1-3 h in vivo. 25 At the indicated time intervals, blood APAP levels was significantly higher in IL-1ra KO mice than in WT mice (Figure 1d ). Intrahepatic GSH can detoxify NAPQI generated from APAP by the conjugation, but there was no significant difference in intrahepatic GSH level between unchallenged WT and IL-1ra KO mice. APAP challenge depleted intrahepatic GSH, to a similar extent, in both strain mice (Figure 1e) . Thus, the absence of IL-1ra impaired NAPQI generation from APAP and the subsequent APAP adduct formation, eventually resulting in the attenuation of APAP hepatotoxicity.
Intrahepatic Expression of Cytochrome P450 Enzymes in the Livers of WT and IL-1ra KO Mice Before and After APAP Challenge Among cytochrome P450 enzymes, CYP1A2, CYP2E1, and CYP3A11 are presumed to be responsible for the generation of NAPQI from APAP. [26] [27] [28] [29] [30] Hence, we next evaluated intrahepatic expression of these enzymes at both mRNA and IL-1ra and APAP-induced liver injury T Ishibe et al protein levels in untreated and treated WT and IL-1ra KO mice. Before APAP challenge, IL-1ra KO mice exhibited reduced mRNA expression of these enzymes, compared with WT mice (Figure 2 ). APAP administration significantly decreased the gene expression of these CYPs in WT mice. Although APAP did have little effects on mRNA expression of these enzymes in IL-1ra KO mice, their gene expression levels were still lower in IL-1ra KO than in WT mice after APAP administration (except for CYP2E1 at 24 h; Figure 2 ). Concomitantly, IL-1ra KO mice exhibited less protein levels of these enzymes, compared with WT mice (Figure 3 ). These observations would indicate that IL-1ra deficiency reduced intrahepatic expression of CYP1A2, CYP2E1, and CYP3A11, the enzymes that could generate NAPQI, a toxic metabolite crucially involved in APAP-induced liver injury.
Intrahepatic NF-jB Activation in WT and IL-1ra KO Mice Before and After APAP Challenge Interleukin-1-mediated signal can activate NF-kB, a transcription factor that can suppress CYP gene transcription. [31] [32] [33] Consistently, IL-1a treatment in WT-derived hepatocytes enhanced NF-kB activation and reciprocally attenuated the expression of CYP1A2, CYP2E1, and CYP3A11, whereas IL-1ra had little effect on NF-kB activation and subsequent expression of these enzymes (Figure 4) . In spite of the absence of significant differences in intrahepatic IL-1a and 
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T Ishibe et al IL-1b contents between untreated WT and IL-1ra KO mice, IL-1ra protein was constitutively expressed in the liver of WT mice (Table 2 ). This may mirror our observations that IL-1ra alone had little effects on IL-1a and IL-1b expression by WT-derived hepatocytes (our unpublished data). Thus, it is highly probable that NF-kB activation can be enhanced by deficiency of IL-1ra, a potent inhibitor of IL-1-mediated NFkB activation. Indeed, nuclear NF-kB p65 protein levels were higher in IL-1ra KO mice than WT mice before APAP challenge, although there were no differences in cytosolic NF-kB p65 proteins between these two strains (Figure 5a and b) . Concomitantly, the amount of NF-kB p65 bound to the corresponding cis element was significantly increased in lL-1ra KO mice, compared with WT mice (Figure 5c ). These observations implied that, under the unstimulated condition, the disruption of IL-1ra resulted in constitutively enhanced NF-kB activation, which eventually led to suppressed expression of CYP1A2, CYP2E1, and CYP3A11. By contrast, APAP increased intrahepatic NF-kB-binding activity in WT mice but not IL-1ra KO ones.
Attenuated APAP-Induced Liver Injury in IL-1ra KO Mice After APAP Challenge Reduced NAPQI generation from APAP in IL-1ra KO mice prompted us to examine APAP-induced liver injury in IL-1ra KO and WT mice. There were no apparent differences in serum ALT levels (WT vs IL-1ra KO: 39.0 ± 2.6 vs 48.4±6.3 IU/l) and histopathological structure (data not shown) between unchallenged WT and IL-1ra KO mice. However, the administration of APAP (200 mg/kg) increased serum ALT levels in WT mice to a higher level than IL-1ra KO mice even at 2 h (WT vs IL-1ra KO: 399 ± 123 vs 98.6 ± 43.0 IU/l, Po0.01) and later thereafter (Figure 6a ). Both WT and IL-1ra KO mice did not exhibit apparent histopathological changes such as centrilobular necrosis and leukocyte recruitment, at 2 h after APAP challenge (Figure 6b ), but the numbers of apoptotic hepatocytes were higher in WT mice than IL-1ra KO mice ( Figure 7 ). Later than 6 h after APAP challenge, WT mice showed more severe histopathological changes including hemorrhages and centrilobular necrosis than IL-1ra KO mice (Figure 6a-c) . Moreover, APAP caused intrahepatic infiltration of both neutrophils and macrophages later than 6 h in WT mice to a larger extent than IL-1ra KO mice (Figure 8 ). We examined the intrahepatic gene expression of proinflammatory cytokines and chemokines in WT and IL-1ra KO mice. Under the used experi- The data were expressed as pg/mg total protein for each sample. IL-1ra and APAP-induced liver injury T Ishibe et al mental conditions, the gene expression of IL-1a, IL-1b, CXCL1/KC, CXCL2/MIP-2, CCL2/MCP-1, and CCL3/MIP1a was faintly detected in the livers of untreated WT and IL-1ra KO mice (Figure 9a ). Later than 6 h APAP challenge, the gene expression of these cytokines and chemokines was augmented in WT mice to larger extents than IL-1ra KO mice (Figure 9b-g ). By contrast, there was no significant difference in the intrahepatic expression of IL-6 and IL-10, the cytokines that had protective roles in APAP-induced liver injury (data not shown). 34, 35 These observations would imply that impaired NAPQI generation in IL-1ra KO mice reduced the initiation of APAP-induced liver injury and subsequent inflammatory reactions as evidenced by reduced IL-1 and chemokine expression.
The Effects of Pretreatment with IL-1a or IL-1ra on APAP-Induced Liver Injury in WT Mice
Finally, we examined the effects of pretreatment of IL-1a on APAP-induced liver injury in vivo. When exogenous IL-1a was administered at 12 h before APAP challenge, it significantly diminished APAP-induced liver injury with reduced APAP adduct amounts (Figure 10a and b) . Moreover, IL-1a reduced the intrahepatic expression levels of CYP1A2, CYP2E1, and CYP3A11 (Figure 10b ). IL-1ra attenuated marginally APAP-induced increases in serum ALT levels when it was administered at 12 h before APAP challenge (data not shown), consistent with the previous report. 17 
DISCUSSION
Inflammatory cytokines, chemokines, and leukocytes are presumed to have detrimental roles in the pathogenesis of APAP-induced liver injury, [5] [6] [7] whereas IL-6, IL-10, and IL-13 can protect the same liver injury. [34] [35] [36] These observations would indicate the essential involvement of inflammatory responses in the development of liver damages caused by APAP.
Accumulating evidence implicates IL-1a and IL-1b as crucial mediators in various inflammatory reaction 11, [13] [14] [15] and their endogenous antagonist, IL-1ra, can inhibit the biological activities of IL-1s by competitive binding to IL-1RI. 8 We previously observed that the sequential treatment with killed Propioniobacteirum acnes and lipopolysaccharide (LPS) caused hepatic necrosis, along with enhanced intrahepatic expression of IL-1ra and IL-1s and that the neutralization of IL-1ra further augmented liver injury. 18 This observation would indicate the protective role of IL-1ra in this liver injury model. Similarly, in APAPinduced liver injury, the intrahepatic expression of IL-1ra was enhanced together with IL-1s (unpublished data). Moreover, neutralization of IL-1 or administration of recombinant IL-1ra attenuated APAP-induced liver injury. 16, 17 This led us to assume that endogenous IL-1ra can prevent or alleviate APAP-induced liver injury. Contrary to our hypothesis, we found that the genetic disruption of IL-1ra alleviated APAP hepatotoxicity. 
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Acetaminophen cannot directly cause hepatotoxicity. It is metabolized mainly by hepatocytes into NAPQI, which is detoxified by GSH. When generated NAPQI depletes GSH, NAPQI covalently binds to cysteine residues on intracellular proteins and induces the formation of 3-(cysteine-S-yl) APAP adducts in hepatocytes. 37, 38 This process is the initial and irreversible step in the development of cell injury. 38, 39 Among several adducts, selenium-binding protein with a molecular weight of 56 kDa, a major APAP adduct, reflects the amounts of generated NAPQI and APAP adducts, 40, 41 and can determine the magnitude of APAP-induced direct liver injury.
2,3 IL-1ra KO-derived hepatocytes exhibited similar sensitivities to NAPQI as WT mouse-derived ones. Moreover, despite no differences of GSH levels, the intrahepatic amount of generated APAP adducts after APAP challenge, was less in IL-1ra KO mice than WT mice. Furthermore, blood APAP concentrations were significantly higher in IL-1ra KO mice than in WT mice after APAP challenge, implying that the absence of IL-1ra impaired APAP metabolism. Collectively, these observations would indicate that the reduced APAPinduced hepatotoxicity in IL-1ra KO mice can arise from decreased NAPQI generation from APAP.
Conversion of APAP into NAPQI is catalyzed by cytochrome P450 enzymes, particularly, CYP1A2, CYP2E1, and CYP3A11. [26] [27] [28] [29] [30] Consistent with our assumption that IL-1ra KO mice may have a reduced capacity to generate NAPQI, the expression of these cytochrome P450 enzymes was diminished at both mRNA and protein levels in IL-1ra KO mice, as compared with WT mice. Proinflammatory cytokines such as IL-1, IL-6, and TNF-a can suppress CYP expression in hepatocytes. [42] [43] [44] [45] Indeed, intrahepatic CYP expression was depressed in inflammation and infection, where these proinflammatory cytokines are presumed to be produced abundantly. 32, 46 Similarly, Liu et al 47 demonstrated that the pretreatment of LPS-sensitive C3H/OuJ mice but not LPS-resistant C3H/HeJ mice with a sublethal dose of LPS attenuated APAP hepatotoxicity by downregulating hepatic P450 enzymes in the livers. Moreover, the administration of both untreated C3H/OuJ and C3H/HeJ mice with IL-1a, alleviated APAP-induced liver injury. 47 IL-1ra KO mice, which lack negative signals for IL-1, expressed IL-1a and IL1b to a similar extent under unstimulated conditions, as WT mice. Thus, it is likely that IL-1-mediated signals were augmented in the livers of IL-1ra KO mice, compared with WT mice, thereby depressing intrahepatic CYP expression.
Several lines of evidence would indicate that the activation of nuclear factor-erythroid 2-related factor 2 (Nrf2) was essential for the detoxification of APAP by inducing the gene expression of phase 2 detoxifying enzymes such as glutathione S-transferases but not phase 1 enzymes such as IL-1ra and APAP-induced liver injury T Ishibe et al cytochrome p450 enzymes. [48] [49] [50] Thus, the differences of CYPs expression between WT and IL-1ra KO mice were not ascribable to Nrf2 activation. Another transcriptional factor, NF-kB, can be activated by various inflammatory stimuli including IL-1 and TNF-a, 31 and is presumed to be involved in CYP gene transcription. Consistently, we demonstrated that IL-1a could enhance NF-kB activation and reciprocally suppressed the expression of CYP1A2, CYP2E1, and CYP3A in cultured WT-derived hepatocytes. APAP challenge augmented intrahepatic IL-1 expression and NF-kB activation to a larger extent in WT than IL-1ra KO mice but the intrahepatic expression of CYP1A2, CYP2E1, and CYP3A11 was still higher in WT mice than IL-1ra KO mice. This seemingly discrepancy may be explained by the fact that CYP expression was higher in untreated WT than IL-1ra KO mice. Higher CYP expression in untreated WT mice could not be cancelled out by APAP-induced IL-1 expression and NF-kB activation.
CYP1A1 and CYP1A2 gene transcription is under the control of aryl hydrocarbon receptor (AhR). 51, 52 Once being activated, NF-kB can interact with AhR and subsequently prevent AhR from activating the transcription of the target genes including CYP1A1 and CYP1A2. 53, 54 Sewer et al 55 demonstrated that the intraperitoneal administration of LPS downregulated the gene expression of CYP2E1 in the livers of rats. Conversely, the administration of curcumin, a NF-kB inhibitor, reversed the gene transcription of CYP2E1 suppressed by LPS in the livers of rats, implying NF-kB as a negative regulator of CYP2E1 transcription. 56 Pregnane X receptor (PXR), also known as steroid and xenobiotic receptor (SXR), can induce CYP3A11 gene transcription through dimerization with retinoid X receptor (RXR). 57, 58 Activated NF-kB can form a heterodimer with RXR, thereby antagonizing PXR/SXR-mediated signaling. 33, 59 These molecular mechanisms may account for downregulation of CYP genes by IL-1 [42] [43] [44] [45] and suppressed CYP1A2, CYP2E1, and CYP3A11 expression observed in IL-1ra KO mice, which is presumed to exhibit enhanced IL-1-mediated signals.
Leukocyte infiltration starts following the appearance of tissue injury. Indeed, intrahepatic leukocyte infiltration be- 
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T Ishibe et al comes apparent later than 6 h after APAP challenge, when liver has already been injured directly by NAPQI toxicity and many hepatocytes became dead. The necrotic hepatocytes are a rich source of IL-1a, 60 which can augment the expression of chemokines and adhesion molecules, thereby inducing the infiltration of leukocytes. 61 Infiltrating leukocytes can produce injurious factors such as proinflammatory cytokines, reactive oxygen species, and NO. 2, 3 The net result is the aggravation of the initial hepatocyte necrosis, which in turn augment IL-1a production and eventually leukocyte recruitment. APAP caused liver injury in mice lacking IFN-g, TNF receptor p55, or CXC chemokine receptor 2, to similar extents as WT mice until 6 h after the challenge, but the injury was alleviated in these gene-deficient mice, thereafter. [5] [6] [7] We further observed that these deficient mice expressed CYPs to similar extents as WT mice (our unpublished data) and therefore, it may be likely that these gene-deficient mice could generate similar amounts of NAPQI as WT mice. On the contrary, serum ALT levels and hepatocyte apoptosis were significantly attenuated in IL-1ra KO even at 2 h after APAP challenge. This may account for subsequent reduction in intrahepatic leukocyte recruitment and liver injury in IL1ra KO mice, later than 6 h after APAP challenge. Moreover, reduced leukocyte recruitment diminished hepatocyte necrosis, and eventually attenuated IL-1 and chemokine expression in IL-1ra KO mice, because they were mainly produced by neutrophils and macrophages during APAPinduced liver injury. Thus, APAP-induced liver injury may consist of two phases: the initiation phase arises from direct hepatotoxicity caused by APAP-derived NAPQI and the later phase arises from leukocyte infiltration and leukocyte-derived cytokines in response to the liver injury in the initiation phase.
There are discrepancies on the effects of the IL-1 axis on APAP hepatotoxicity. Blazka et al 17 demonstrated that IL-1ra reduced marginally APAP-induced liver injury, similarly as we observed here (our unpublished data). On the contrary, Liu et al 47 demonstrated when IL-1a was given 12 or 24 h before APAP challenge, it attenuated susceptibility to APAP toxicity, together with reduced intrahepatic CYP expression, as similarly observed on IL-1ra KO mice. Thus, the IL-1 axis can suppress intrahepatic CYP expression with latency, thereby depressing NAPQI generation from APAP. Simultaneously, the IL-1 axis can perpetuate inflammatory reactions by inducing the expression of proinflammatory molecules such as TNF and chemokines in recruited leukocytes, thereby augmenting organ damage at the later phase. These doubleedged actions of the IL-1 axis may account for the observed discrepancies.
The present observations indicate that the IL-1 axis has profound effects on APAP-induced toxicities. APAP is generally a safe antipyretic but can cause serious adverse effects to some patients. 1 Given the presence of the polymorphisms of the IL-1 family genes, 62 these polymorphisms of IL-1s may affect the sensitivities to APAP. If so, typing of human IL-1 family gene polymorphisms may help to decide the doses of APAP in individuals.
